Invention Grant
- Patent Title: Dengue vaccine unit dose and administration thereof
-
Application No.: US16561953Application Date: 2019-09-05
-
Publication No.: US11590221B2Publication Date: 2023-02-28
- Inventor: Derek Wallace
- Applicant: Takeda Vaccines, Inc.
- Applicant Address: US MA Cambridge
- Assignee: Takeda Vaccines, Inc.
- Current Assignee: Takeda Vaccines, Inc.
- Current Assignee Address: US MA Cambridge
- Agency: Honigman LLP
- Agent Fernando Alberdi; Jonathan P. O'Brien
- Priority: EP18192701 20180905,EP18192711 20180905,EP18192717 20180905,EP18192776 20180905,EP18192787 20180905,EP18192793 20180905,EP18192800 20180905,EP18192814 20180905,EP19154334 20190129,EP19161184 20190307
- Main IPC: A61K39/295
- IPC: A61K39/295 ; A61P31/14 ; A61K35/76 ; A61K39/00
Abstract:
The invention relates to a unit dose of a dengue vaccine composition and methods and uses for preventing dengue disease and methods for stimulating an immune response to all four dengue virus serotypes in a subject or subject population. The unit dose of a dengue vaccine composition includes constructs of each dengue serotype, such as TDV-1, TDV-2, TDV-3 and TDV-4, at various concentrations in order to improve protection from dengue infection.
Public/Granted literature
- US20200230230A1 DENGUE VACCINE UNIT DOSE AND ADMINISTRATION THEREOF Public/Granted day:2020-07-23
Information query
